Examples of using Xiapex in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Visually inspect the vial containing Xiapex.
After each injection of Xiapex, your penis may be wrapped with a bandage.
Data on the long term recurrence rates following successful treatment with Xiapex are provided in Table 7.
Xiapex is comprised of a mixture of Class I(AUX-I) and Class II(AUX-II) clostridial collagenases in a defined mass ratio.
There are no known interactions withconcomitant use of medicines for erectile dysfunction and Xiapex treatment.
People also translate
There is no relevant use of Xiapex in the paediatric population aged 0-18 years for the treatment of Dupuytren's contracture.
Only the supplied solvent must be used for reconstitution;it contains calcium which is required for the activity of Xiapex.
The vial containing Xiapex and the vial containing the solvent for solution for injection for reconstitution must be refrigerated.
The potential for a serious allergic reaction orthe development of a musculoskeletal syndrome upon repeated use of Xiapex cannot be excluded.
Xiapex treatment significantly improved penile curvature deformity in patients with Peyronie's disease compared with placebo Table 9.
The most frequently reported adverse drug reactions(≥25%) during the Xiapex controlled clinical studies were penile haematoma, penile swelling and penile pain.
Xiapex must not be used to treat Peyronie's disease if the plaque affects the urethra the tube that carries urine and semen to the outside.
A significant mean improvement(74.4%) from baseline to Day 31 was observed overall in fixed flexioncontracture following administration of two concurrent injections of Xiapex 0.58 mg(one injection per joint) in the same hand, see Table 6.
There is no relevant use of Xiapex in children and adolescents aged 0-18 years for the treatment of Dupuytren's contracture or Peyronie's disease.
Xiapex is a lyophilized product for parenteral administration containing collagenase clostridium histolyticum which is comprised of two collagenases in a defined mass ratio.
There were no other clinically relevant differences between two concurrent injections of Xiapex in the same hand and up to three single injections of Xiapex in the types of adverse events reported ie, most adverse events were local to the treated extremity and of mild or moderate intensity.
Xiapex must be administered by a physician appropriately trained in the correct administration of the medicinal product and experienced in the diagnosis and treatment of male urological diseases.
The incidence of skin laceration(29.1%)was higher for subjects treated with two concurrent injections of Xiapex in historically-controlled clinical study AUX-CC-867 compared with subjects treated with up to three single injections in the Phase 3 placebo-controlled pivotal studies in Dupuytren's contracture(CORD I and CORD II) 8.8.
Xiapex also demonstrated a clinically significant benefit compared to placebo in decreasing the degree of contracture and increasing both the range of motion from baseline for all joints treated(MP plus PIP, MP only, PIP only) and the subject global assessment of treatment satisfaction.
Recurrence was assessed in successfully treated joints(i.e., subjects had a reduction in contractureto 5° or less at the Day 30 evaluation after the last injection of Xiapex in a previous study) and was defined as an increase in joint contracture by at least 20° in the presence of a palpable cord, or the joint underwent medical or surgical intervention primarily to correct a new or worsening Dupuytren's contracture in that joint.
The efficacy of Xiapex 0.58 mg was evaluated in two pivotal randomized, double-blind, placebo- controlled studies, CORD I(AUX-CC-857) and CORD II(AUX-CC-859), in adult patients with Dupuytren's contracture.
The MAH shallensure that all physicians who are expected to prescribe/use Xiapex are appropriately trained in the correct administration of the medicinal product and experienced in the diagnosis and management of Dupuytren's contracture and Peyronie's disease.
Therefore, Xiapex must be injected only into the Peyronie's plaque and care should be taken to avoid injecting into the urethra, nerves, blood vessels, corpora cavernosa or other collagen-containing structures of the penis.
One to three days after the second injection of Xiapex in a treatment cycle, you will need to return to your doctor for a manual procedure that will help stretch and help straighten your penis.
Xiapex treatment in patients having a calcified plaque that could have interfered with the injection technique, chordee in the presence or absence of hypospadias, thrombosis of the dorsal penile artery and/or vein, infiltration by a benign or malignant mass resulting in penile curvature, infiltration by an infectious agent, such as in lymphogranuloma venereum, ventral curvature from any cause and isolated hourglass deformity of the penis has not been studied and treatment in these patients should be avoided.
Clinical study experience with Xiapex is currently limited to four treatment cycles in which a total of 8 injections may be administered into the plaque causing the curvature.
The efficacy of Xiapex was evaluated in two randomized, double-blind, placebo-controlled studies, Study 1(AUX-CC-803) and Study 2(AUX-CC-804), in adult males with Peyronie's disease.
Because the collagen lysis process following Xiapex administration is localized and does not require or result in quantifiable systemic levels of AUX-I and AUX-II, the primary pharmacodynamic activity of Xiapex cannot be evaluated in subjects and therefore, such studies have not been undertaken.
Following administration of either a single dose of 0.58 mg of Xiapex to 16 patients with Dupuytren's contracture, or two concurrent injections of 0.58 mg of Xiapex in the same hand in 12 patients with Dupuytren's contracture, no quantifiable levels of Xiapex were detected in plasma from 5 minutes to 30 days post injection.
The most frequently reported adverse reactions during the Xiapex clinical studies(272 of 409 patients received up to three single injections of Xiapex and 775 patients received two concurrent injections in the same hand) were local injection site reactions such as oedema peripheral(local to the injection site), contusion(including ecchymosis), injection site haemorrhage and injection site pain.